Stocks Primed For Double-Digit Gains: Park Hotels & Resorts Inc. (PK), Ironwood Pharmaceuticals, Inc. (IRWD) – The RNS Daily

This post was originally published on this site

The shares of Park Hotels & Resorts Inc. (NYSE:PK) dropped by -6.76% or -$2.29 from its last recorded high of $33.88 which it attained on July 09 to close at $31.59 per share. Over the past 52 weeks, the shares of Park Hotels & Resorts Inc. has been trading as low as $25.06 before witnessing a massive surge by 26.06% or $6.53. This price movement has led to the PK stock receiving more attention and has become one to watch out for. It dipped by -0.97% on Monday and this got the market worried. The stock’s beta now stands at 0 and when compared to its 200-day moving average and its 50-day moving average, PK price stands 3.75% above and 1.66% above respectively. Its average daily volatility for this week is 1.71% which is more than the 1.68% recorded over the past month.

Park Hotels & Resorts Inc. (PK) sank -1.83% this week, a trend that has led to both investors and traders taking note of the stock. Over the past one year, the equity price has embarked on a rally that has seen it rise 16.26% and is now up by 21.59% since start of this year. A look at its monthly performance shows that the stock has recorded a 0.67% gain over the past 30 days. Its equity price climbed by 11.82% over the past three months which led to its overall six-month increase to stand at 8.08%.

A look at PK technical analysis shows that its 14-day Relative Strength Index (RSI) is in a neutral zone after reaching 52.14 point. Its trading volume has lost -533921 shares compared to readings over the past three months as it recently exchanged 1006079 shares. This means there is reduced activity from short-term traders as per session, its average trading volume is 1540000 shares, and this is 0.65 times the normal volume.

The price of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) currently stands at $11.4 after it went down by $-0.08 or -0.7% and has found a strong support at $11.24 a share. If the IRWD price drops below that critical support, then it would lead to a bearish trend. In the short-term, a dip below the $11.07 mark would also be bad for the stock as it means that the stock would plunge by 2.89% from its current position. However, if the stock price is able to trade above the resistance point around $11.59, then it could likely surge higher to try and break the upward resistance which stands at $11.77 a share. Its average daily volatility over the past one month stands at 4.58%. The stock has plunged by 1.23% from its 52-weeks high of $11.26 which it reached on Jul. 13, 2018. In general, it is 33.42% above its 52-weeks lowest point which stands at $7.59 and this setback was observed on Dec. 24, 2018.

Analysts have predicted a price target for Ironwood Pharmaceuticals, Inc. (IRWD) for 1 year and it stands at an average $14.08/share. This means that it would likely increase by 23.51% from its current position. The current price of the stock has been moving between $11.26 and $11.61. Some brokerage firms have a lower target for the stock than the average, with one of them setting a price target as low as $10.04. On the other hand, one analyst is super bullish about the price, setting a target as high as $18.

The IRWD stock Stochastic Oscillator (%D) is at 12.22%, which means that it is currently oversold and its prices could jump very soon. The shares P/S ratio stands at 5 which compares to the 44.2 recorded by the industry or the 9 by the wider sector. The stock currently has an estimated price-earnings (P/E) multiple of 24.41, which is higher than the 0 multiple of 12-month price-earnings (P/E). The company’s earnings have gone up, with a quarterly increase rate of 4.7% over the past five years.

Analysts view Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) as a Hold, with 2.6 consensus rating. Reuters surveyed 12 analysts that follow IRWD and found that 7 of those analysts rated the stock as a Hold. The remaining 5 were divided, with 4 analyst rating it as a Buy or a Strong Buy while 1 analysts advised investors to desist from buying Ironwood Pharmaceuticals, Inc. (IRWD) shares or sell it if they already own it.

This post was originally published on *this site*